Literature DB >> 121258

[Semi-synthesis and proposed structure of platelet-activating factor (P.A.F.): PAF-acether an alkyl ether analog of lysophosphatidylcholine].

J Benveniste, M Tencé, P Varenne, J Bidault, C Boullet, J Polonsky.   

Abstract

We have studied the molecular structure of platelet-activating factor" (P.A.F.), a mediator of inflammation obtained from blood leukocytes, macrophages, and platelets themselves. We have semi-synthetized a substance that possesses all the known physicochemical and biological characteristics of P.A.F. from hog leukocytes. This was performed by successive methylation, hydrogenation, and acetylation of lysophosphatidylethanolamine plasmalogen. We therefore propose the following structure for P.A.F.: 1-0-alkyl-2-acetyl-glyceryl-3-phosphorylcholine. This molecular structure is not yet described among the numerous substances capable of inducing platelet aggregation and release.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 121258

Source DB:  PubMed          Journal:  C R Seances Acad Sci D        ISSN: 0567-655X


  97 in total

Review 1.  Lipid acetylation reactions and the metabolism of platelet-activating factor.

Authors:  R R Baker
Journal:  Neurochem Res       Date:  2000-05       Impact factor: 3.996

2.  Reversible or irreversible modification of [3H]PAF binding on rabbit platelet membranes differentiates various PAF receptor antagonists.

Authors:  M T Domingo; F Piro; C Broquet; E Auclair; P E Chabrier; P Braquet
Journal:  Lipids       Date:  1992-08       Impact factor: 1.880

Review 3.  The pharmacology of airway hyperresponsiveness and inflammation.

Authors:  R Pauwels
Journal:  Lung       Date:  1990       Impact factor: 2.584

4.  The effect of intravenous administration of WEB 2086 on PAF-induced platelet aggregation in healthy Friesian calves.

Authors:  M B Bastos da Silva; P Gustin; F Herion; R Raskinet; J L David; T Gougnard; G Plomteux; D Desmecht; P Lekeux
Journal:  Vet Res Commun       Date:  1997-10       Impact factor: 2.459

5.  Interaction of the Paf antagonist WEB 2086 and its hetrazepine analogues with human platelets and endothelial cells.

Authors:  R Korth; M Hirafuji; C L Keraly; D Delautier; J Bidault; J Benveniste
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

6.  Human platelets stimulated by thrombin produce platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when the degrading enzyme acetyl hydrolase is blocked.

Authors:  L Touqui; M Hatmi; B B Vargaftig
Journal:  Biochem J       Date:  1985-08-01       Impact factor: 3.857

7.  Neutropenia induced by platelet-activating factor (PAF-acether) released from neutrophils: the inhibitory effect of prostacyclin (PGI2).

Authors:  G Camussi; C Tetta; G Segoloni; M Chiara Deregibus; F Bussolino
Journal:  Agents Actions       Date:  1981-12

8.  Arachidonyl transfer from diacyl phosphatidylcholine to ether phospholipids in rat platelets.

Authors:  O Colard; M Breton; G Bereziat
Journal:  Biochem J       Date:  1984-09-15       Impact factor: 3.857

9.  Treatment of carrageenan induced arthritis by the platelet activating factor antagonist BN 50730.

Authors:  P Hilliquin; J Natour; J Aissa; P Guinot; S Laoussadi; J Benveniste; C J Menkes; B Arnoux
Journal:  Ann Rheum Dis       Date:  1995-02       Impact factor: 19.103

10.  Platelet activating factor: an inhibitor of neutrophil activation?

Authors:  M C O'Donnell; J N Siegel; B A Fiedel
Journal:  Clin Exp Immunol       Date:  1981-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.